A detailed history of Uniplan Investment Counsel, Inc. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Uniplan Investment Counsel, Inc. holds 53,104 shares of LGND stock, worth $6.09 Million. This represents 0.49% of its overall portfolio holdings.

Number of Shares
53,104
Previous 49,617 7.03%
Holding current value
$6.09 Million
Previous $4.18 Million 27.25%
% of portfolio
0.49%
Previous 0.38%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$82.7 - $110.11 $288,374 - $383,953
3,487 Added 7.03%
53,104 $5.32 Million
Q2 2024

Aug 14, 2024

BUY
$68.53 - $87.91 $576,748 - $739,850
8,416 Added 20.43%
49,617 $4.18 Million
Q1 2024

May 15, 2024

BUY
$68.64 - $89.2 $2.83 Million - $3.68 Million
41,201 New
41,201 $3.01 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.94B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Uniplan Investment Counsel, Inc. Portfolio

Follow Uniplan Investment Counsel, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Uniplan Investment Counsel, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Uniplan Investment Counsel, Inc. with notifications on news.